Combinatorial, additive and dose-dependent drug–microbiome associations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Sofia K. Forslund
  • Rima Chakaroun
  • Maria Zimmermann-Kogadeeva
  • Lajos Markó
  • Judith Aron-Wisnewsky
  • Nielsen, Trine
  • Lucas Moitinho-Silva
  • Thomas S.B. Schmidt
  • Gwen Falony
  • Sara Vieira-Silva
  • Solia Adriouch
  • Renato J. Alves
  • Karen Assmann
  • Jean Philippe Bastard
  • Till Birkner
  • Robert Caesar
  • Julien Chilloux
  • Luis Pedro Coelho
  • Leopold Fezeu
  • Nathalie Galleron
  • Gerard Helft
  • Richard Isnard
  • Boyang Ji
  • Michael Kuhn
  • Emmanuelle Le Chatelier
  • Antonis Myridakis
  • Lisa Olsson
  • Nicolas Pons
  • Edi Prifti
  • Benoit Quinquis
  • Hugo Roume
  • Christian Lewinter
  • Nadja B. Søndertoft
  • Helle Krogh Pedersen
  • Tue H. Hansen
  • Hartmann, Bolette
  • Holst, Jens Juul
  • Malene Hornbak
  • Jørgensen, Niklas Rye
  • Justesen, Johanne Marie
  • Nikolaj Krarup
  • Mathilde Svendstrup
  • The MetaCardis Consortium*

During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1–5. Here, through integrated multi-omics analyses of 2,173 European residents from the MetaCardis cohort, we show that the explanatory power of drugs for the variability in both host and gut microbiome features exceeds that of disease. We quantify inferred effects of single medications, their combinations as well as additive effects, and show that the latter shift the metabolome and microbiome towards a healthier state, exemplified in synergistic reduction in serum atherogenic lipoproteins by statins combined with aspirin, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers. Several antibiotics exhibit a quantitative relationship between the number of courses prescribed and progression towards a microbiome state that is associated with the severity of cardiometabolic disease. We also report a relationship between cardiometabolic drug dosage, improvement in clinical markers and microbiome composition, supporting direct drug effects. Taken together, our computational framework and resulting resources enable the disentanglement of the effects of drugs and disease on host and microbiome features in multimedicated individuals. Furthermore, the robust signatures identified using our framework provide new hypotheses for drug–host–microbiome interactions in cardiometabolic disease.

OriginalsprogEngelsk
TidsskriftNature
Vol/bind600
Sider (fra-til)500-517
Antal sider18
ISSN0028-0836
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
Acknowledgements We thank the MetaCardis participants for their participation in the study, and particularly the patient associations (Alliance du Coeur and CNAO) for their input and interface; D. Bonnefont-Rousselot (Department of Metabolic Biochemistry, Pitié-Salpêtrière Hospital) for the analysis of plasma lipid profiles; and the nurses, technicians, clinical research assistants and data managers from the Clinical Investigation Platform at the Institute of Cardiometabolism and Nutrition for patient investigations, the Clinical Investigation Center (CIC) from Pitié-Salpêtrière Hospital and Human Research Center on Nutrition (CRNH Ile-de-France) as well as the university hospital of Leipzig for the investigation of healthy control individuals. Quanta Medical provided regulatory oversight of the clinical study and contributed to the processing and management of electronic data. This work was supported by the European Union’s Seventh Framework Program for research, technological development and demonstration under grant agreement HEALTH-F4-2012-305312 (METACARDIS). Part of this work was also supported by the EMBL, by the Metagenopolis grant ANR-11-DPBS-0001, by the H2020 European Research Council (ERC-AdG-669830) (to P.B.), and by grants from the Deutsche Forschungsgemeinschaft (SFB1365 to S.K.F. and L.M.; and SFB1052/3 A1 MS to M.S. (209933838)). Assistance Publique-Hôpitaux de Paris is the promoter of the clinical investigation (MetaCardis). M.-E.D. is supported by the NIHR Imperial Biomedical Research Centre and by grants from the French National Research Agency (ANR-10-LABX-46 (European Genomics Institute for Diabetes)), from the National Center for Precision Diabetic Medicine – PreciDIAB, which is jointly supported by the French National Agency for Research (ANR-18-IBHU-0001), by the European Union (FEDER), by the Hauts-de-France Regional Council (Agreement 20001891/NP0025517) and by the European Metropolis of Lille (MEL, Agreement 2019_ESR_11) and by Isite ULNE (R-002-20-TALENT-DUMAS), also jointly funded by ANR (ANR-16-IDEX-0004-ULNE), the Hauts-de-France Regional Council (20002845) and by the European Metropolis of Lille (MEL). R.J.A. is a member of the Collaboration for joint PhD degree between EMBL and Heidelberg University, Faculty of Bioscience. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research institution at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation.

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.

ID: 287612631